Éric Jourdan

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis

Animesh Pardanani, Claire Harrison, Jörge E. Cortes et al. · JAMA Oncology · 2015 · 472 citations

Medicine, Hematology, Pharmacology +14

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

Claire Harrison, Nicolaas Schaap, Alessandro M. Vannucchi et al. · The Lancet Haematology · 2017 · 330 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +5

Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin’s Lymphoma: Results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study

Bertrand Coiffier, Nicolas Mounier, Serge Bologna et al. · Journal of Clinical Oncology · 2003 · 240 citations

Medicine, Pharmacology, Pharmacotherapy +14

A DNA Aptamer as a New Target-Specific Chiral Selector for HPLC

Mickaël Michaud, Éric Jourdan, Annick Villet et al. · Journal of the American Chemical Society · 2003 · 198 citations

Pharmacy, Biochemistry, Biophysical Chemistry +16

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the <scp>JAKARTA2</scp> study using stringent criteria for ruxolitinib failure

Claire Harrison, Nicolaas Schaap, Alessandro M. Vannucchi et al. · American Journal of Hematology · 2020 · 148 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13